Welltower Inc. (WELL) Stock Price & Analysis
Welltower Inc. (WELL) closed at USD 237.4 on Thursday, October 22, 2026, up 1.37% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 234.19; the Oct 22, 2026 session ranged USD 234.25–238.27 on volume of 2,349,979 shares. Market capitalization is $171.06B, with a 52-week range of USD 174.91–255.2 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 11:43 UTC.
Also available as compact Markdown for AI agents: nexqual.com/WELL.md
Key facts (WELL)
- Last four reported quarters (through Jun 30, 2026): revenue $12.8B, net income $1.62B (12.7% margin), free cash flow $2.02B (SEC filings).
- Valuation: P/E 105.9x (avg 113.5x at the last 3 fiscal year-ends), net debt $15.8B.
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $2.4M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.91 on a 1–5 scale) (22 analysts), mean target USD 260.55 (range 219–292).
- Total return with dividends: 1Y +36.8% vs S&P 500 +14.9%; 5Y +230.2% vs S&P 500 +80.3%.
- Next earnings: 2026-10-26, EPS estimate USD 0.71, revenue estimate $3.75B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (WELL)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $4.74B | $5.86B | $6.64B | $7.99B | $10.8B | $12.8B |
| Gross profit | $1.97B | $2.30B | $2.69B | $3.16B | $4.35B | — |
| Net income | $374M | $161M | $358M | $973M | $962M | $1.62B |
| EPS (diluted) | $0.78 | $0.30 | $0.66 | $1.57 | $1.39 | — |
| Free cash flow | $993M | $853M | $1.08B | $1.40B | $1.83B | $2.02B |
| Gross margin | 41.5% | 39.3% | 40.5% | 39.6% | 40.1% | — |
| Net margin | 7.9% | 2.7% | 5.4% | 12.2% | 8.9% | 12.7% |
| Revenue growth | +3.0% | +23.6% | +13.3% | +20.4% | +35.6% | — |
| Cash + short-term investments | $269M | $632M | $1.99B | $3.51B | $5.03B | — |
| Total debt | $13.9B | $14.7B | $15.7B | $15.5B | $19.2B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (WELL)
P/E 105.9x · P/S 13.4x · EV/Sales 14.6x · P/FCF 84.7x · P/B 3.7x · FCF yield 1.18% · Earnings yield 0.94% · Dividend yield (paid, TTM) 1.20% · Net debt $15.8B · EV $187B
P/E at fiscal year-ends: Dec 2025 131.1x, Dec 2024 78.9x, Dec 2023 130.6x.
Insider purchases (SEC Form 4, open-market, last ~7 months) (WELL)
1 purchase, $2.4M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-25…2026-08-26 | Gundlach Andrew | Director | 10,000 | $2.4M | 240.76 | Too little history (no open-market trades in 2023 or 2024) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (WELL)
Consensus Buy (mean 1.91 on a 1–5 scale), 22 analysts; mean target USD 260.55 (low 219, high 292).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | Wells Fargo | Target raised | Overweight | $266 → $268 |
| 2026-10-13 | Barclays | Target lowered | Equal-Weight | $259 → $246 |
| 2026-09-24 | JP Morgan | Upgrade | Neutral → Overweight | $260 |
| 2026-09-21 | Evercore ISI Group | Target lowered | Outperform | $260 → $256 |
| 2026-09-02 | Scotiabank | Target raised | Sector Outperform | $244 → $251 |
| 2026-09-01 | Morgan Stanley | Target raised | Overweight | $215 → $251 |
| 2026-09-01 | Wells Fargo | Target raised | Overweight | $237 → $266 |
| 2026-08-31 | Barclays | Target raised | Equal-Weight | $254 → $259 |
| 2026-08-04 | Keybanc | Target raised | Overweight | $240 → $275 |
| 2026-08-03 | RBC Capital | Target raised | Outperform | $238 → $260 |
| 2026-07-31 | Citigroup | Target raised | Buy | $255 → $275 |
| 2026-07-31 | Cantor Fitzgerald | Target raised | Overweight | $235 → $260 |
Total return (dividends reinvested) (WELL)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +36.8% | +230.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +37.0% | +26.9% |
| Volatility (annualized) | 22.8% | 24.0% |
| Max drawdown | -12.6% (Nov 2025→Jan 2026) | -40.0% (Mar 2022→Oct 2022) |
WELL revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Seniors Housing Operating | $2.98B | 84.2% | +51.4% |
| Total revenue | $3.54B | 100% | — |
WELL revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $2.13B | 60.1% | +9.6% |
| United Kingdom | $1.13B | 31.8% | +170.4% |
| Canada | $285.7M | 8.1% | +52.7% |
| Total revenue | $3.54B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
WELL suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Welltower OP | “We are structured as an umbrella partnership REIT, or "UPREIT," under which substantially all of our business is conducted through Welltower OP LLC ("Welltower OP"), the day-to-day management of which is exclusively controlled by Welltower Inc.” |
Quoted from the company's 10-K filed Feb 12, 2026.
Companies that name WELL in their SEC reports
| Relationship to WELL | Company | Filing | Sentence |
|---|---|---|---|
| partner | Brookdale Senior Living Inc. (BKD) | 10-K Feb 19, 2026 | “In September 2024, the Company entered into a definitive agreement to acquire 11 senior living communities that were leased by the Company from a joint venture between Welltower Inc. ("Welltower") and its joint venture partners for a purchase price of $300.0 million.” |
WELL company outlook (results filed Jul 27, 2026)
- “Outlook for 2026 Net income attributable to common stockholders guidance has been revised to a range of $3.11 to $3.19 per diluted share from the previous range of $3.24 to $3.38.”
- “We also increased the guidance range of full year normalized FFO attributable to common stockholders to a range of $6.36 to $6.44 per diluted share from the previous range of $6.21 to $6.35.”
- “This includes approximately $0.8 billion of consideration from expected property sales, which predominantly includes announced OM and Integra dispositions and land parcels related to foregone development, as well as $0.3 billion of expected proceeds from loan repayments.”
- “Our guidance does not include any additional investments, dispositions or capital transactions, nor any other expenses, impairments, unanticipated additions to the loan loss reserve or other additional normalizing items beyond those disclosed.”
Quoted word-for-word from the SEC 8-K results press release.
WELL analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.71 | $0.67 | +6.8% | $3.75B | 1 |
| Next quarter (ends Dec 2026) | $0.67 | $0.69 | -2.9% | $3.96B | 1 |
| Current fiscal year (ends Dec 2026) | $2.88 | $3.01 | -4.3% | $14.45B | 1 |
| Next fiscal year (ends Dec 2027) | $3.20 | $3.36 | -4.8% | $16.66B | 2 |
WELL options: expected move
Options price a move of about ±6.6% (±$15.70) by Nov 20, 2026, which includes earnings on Oct 26, 2026. Over the last 8 reports the stock moved ±3.1% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 28.9% | ±6.6% |
| Dec 18, 2026 | 56 | 26.1% | ±8.3% |
| Jan 15, 2027 | 84 | 25.0% | ±9.7% |
| Feb 19, 2027 | 119 | 25.4% | ±11.7% |
| Mar 19, 2027 | 147 | 25.8% | ±13.1% |
| May 21, 2027 | 210 | 25.3% | ±15.3% |
| Jun 17, 2027 | 237 | 25.7% | ±16.5% |
| Aug 20, 2027 | 301 | 25.9% | ±18.6% |
30-day implied volatility 27.6% vs 18.7% realized over the last 30 trading days. Put/call ratio (volume) 1.11. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 11:43 UTC)
| Price | USD 237.4 |
|---|---|
| Change | ▲ 1.37% (up) |
| Previous Close | USD 234.19 |
| Open | USD 235.11 |
| Day Range | USD 234.25 – 238.27 |
| 52-Week Range | USD 174.91 – 255.2 |
| Volume | 2,349,979 shares |
| Market Cap | $171.06B |
| Exchange | NYQ |
Technical Analysis (WELL)
Nexqual's technical model rates WELL "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 11:43 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 57.93 (neutral) |
| vs SMA50 | Above (USD 233.73) |
| MACD | 0.89 (positive) |
Analyst Ratings (WELL)
Wall Street analysts rate WELL "Buy" based on 22 analysts, with a mean price target of USD 260.55 (range USD 219–292), per Nexqual as of October 23, 2026 at 11:43 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 22 |
| Mean Target | USD 260.55 |
| High Target | USD 292 |
| Low Target | USD 219 |
| Buy / Hold / Sell | 18 / 4 / 0 |
Earnings (WELL)
| Next Earnings Date | 2026-10-26 |
|---|---|
| EPS Estimate | USD 0.71 |
| Revenue Estimate | $3.75B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.54 vs est 0.65 ▼ miss |
| 2026-03-31 | USD 0.55 vs est 0.5 ▲ beat |
| 2025-12-31 | USD 0.55 vs est 0.59 ▼ miss |
| 2025-09-30 | USD 0.55 vs est 0.53 ▲ beat |
Source: Nexqual, October 23, 2026 at 11:43 UTC.
Financials & Fundamentals (WELL)
| Total Revenue | $12.76B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +39.10% |
| Gross Margin | +39.56% |
| Operating Margin | +16.56% |
| Profit Margin | +12.15% |
| ROE | +3.84% |
| Debt / Equity | 0.41 |
| Current Ratio | 1.32 |
| Total Cash | $1.97B |
| Total Debt | $19.72B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $2.02B (15.8% of revenue) |
Source: Nexqual, October 23, 2026 at 11:43 UTC.
Financial Health Score (WELL)
Nexqual rates Welltower Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 11:43 UTC.
| Growth | Strong — Revenue +36% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 40%, operating 17% (last 12 months) |
| Balance Sheet | Solid — $1.97B cash and investments vs $17.7B debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $2.02B (last 4 quarters to Jun 2026, SEC), 16% margin |
| Efficiency | Weak — ROE 4%, ROA 0.8% |
Ownership (WELL)
| Insider Ownership | +0.06% |
|---|---|
| Institutional Ownership | +100.85% |
| Shares Outstanding | 720.57M |
| Float | 719.74M |
| Short % of Float | +2.79% |
Source: Nexqual, October 23, 2026 at 11:43 UTC.
Leadership (WELL)
Welltower Inc. is led by Shankh S. Mitra, CEO & Director, per Nexqual as of October 23, 2026 at 11:43 UTC.
| CEO & Director | Shankh S. Mitra |
|---|---|
| Co-President & CFO | Timothy G. McHugh C.F.A. |
| Co-President & Chief Investment Officer | Nikhil Chaudhri |
| Vice Chairman & COO | John F. Burkart |
| Chief Technology Officer | Jeff Stott |
Major Backers & Investors (WELL)
Notable institutional backers of Welltower Inc. include Capital International Investors, Cohen & Steers Inc., Capital Group, according to Nexqual as of October 23, 2026 at 11:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital International Investors | 5.48% |
| Cohen & Steers Inc. | 5.11% |
| Capital Group | 2.78% |
| Bank of America Corporation | 2.71% |
| FMR, LLC | 2.7% |
| Price (T.Rowe) Associates Inc | 2.57% |
| WASHINGTON MUTUAL INVESTORS FUND | 2.26% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 12.43% |
| BlackRock | 10.83% |
| State Street | 5.85% |
Source: Nexqual, October 23, 2026 at 11:43 UTC.
From Welltower Inc.'s Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Through our disciplined approach to capital allocation powered by our Data Science platform and superior operating results driven by the Welltower Business System - our end-to-end platform - we aspire to deliver long-term compounding of per share growth for our existing investors.
- Finally, data privacy and security laws and regulations continue to develop, including with regard to HIPAA, privacy and security standards enforced by the Federal Trade Commission, and U.S. state privacy laws governing consumer personal data and consumer health data.
Partnerships
- Properties can be held in joint venture entities with operating partners and we may utilize the structure authorized by the REIT Investment Diversification and Empowerment Act of 2007 ("RIDEA"), which is commonly referred to as a "RIDEA" structure.
- Implementation is phased and conducted in collaboration with our operating partners, and we monitor adoption and effectiveness through standardized KPIs and reporting routines.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VTR | Ventas, Inc. | USD 86.99 | ▲ 1.89% |
| OHI | Omega Healthcare Investors, Inc | USD 46.3 | ▲ 4.16% |
| DOC | Healthpeak Properties, Inc. | USD 19.34 | ▲ 4.65% |
| AHR | American Healthcare REIT, Inc. | USD 53.4 | ▲ 1.02% |
| CTRE | CareTrust REIT, Inc. | USD 36.62 | ▲ 2.72% |
| HR | Healthcare Realty Trust Incorpo | USD 17.93 | ▲ 4% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 11:43 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt